Margaret A. Honein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Margaret A. Honein has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
Coleen Boyle
Centers for Disease Control and Prevention, Atlanta, Georgia
3 shared publicationsCynthia A. Moore
Division of Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA
3 shared publications- Angelica Rico
Division of Research in Public Health, National Institute of Health, Bogota, Colombia
2 shared publications - Diana Valencia
Division of Infectious Disease Readiness and Innovation, Centers for Disease Control and Prevention, Atlanta, GA, USA
2 shared publications - Jennifer Dolan Thomas
Center for Behavioral Teratology San Diego State University San Diego California USA
2 shared publications - Jessica N. Ricaldi
Division of Infectious Diseases, Department of Medicine, University of California San Diego School of Medicine, La Jolla, California, United States of America
2 shared publications
Latest Publications
- 9 July 2024
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. -1 (aop) , 622-626
Birth Outcomes Related to Prenatal Zika, Dengue, and Other Flavivirus Infections in the Zika en Embarazadas y Niños Prospective Cohort Study in Colombia
Zika virus (ZIKV) infection in pregnancy is associated with severe abnormalities of the brain and eye and other adverse outcomes. Zika en Embarazadas y Niños was a prospective cohort study conducted in multiple Colombian cities that enrolled pregnant women in their first trimester. Specimens collected from pregnant women (n = 1,519) during February 2017–September 2018 and their infants (n = 1,080) during June 2017–March 2019 were tested for prenatal ZIKV infection by nucleic acid amplification tests or IgM antibody testing. Zika virus infection in pregnancy was present in 3.2% of pregnant women (incidence rate [IR] per 1,000 person-months = 5.9, 95% CI: 4.3–7.8). Presumptive ZIKV infection was present in 0.8% of infants (IR = 1.6, 95% CI: 0.7–2.9). Five percent of infants with prenatal ZIKV exposure or infection presented with Zika-associated abnormalities; 4.7% were small for gestational age. Understanding the risk of ZIKV infection during pregnancy and associated adverse outcomes can help inform counseling efforts.
- 9 July 2024
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. -1 (aop) , 622-626
Birth Outcomes Related to Prenatal Zika, Dengue, and Other Flavivirus Infections in the Zika en Embarazadas y Niños Prospective Cohort Study in Colombia
Zika virus (ZIKV) infection in pregnancy is associated with severe abnormalities of the brain and eye and other adverse outcomes. Zika en Embarazadas y Niños was a prospective cohort study conducted in multiple Colombian cities that enrolled pregnant women in their first trimester. Specimens collected from pregnant women (n = 1,519) during February 2017–September 2018 and their infants (n = 1,080) during June 2017–March 2019 were tested for prenatal ZIKV infection by nucleic acid amplification tests or IgM antibody testing. Zika virus infection in pregnancy was present in 3.2% of pregnant women (incidence rate [IR] per 1,000 person-months = 5.9, 95% CI: 4.3–7.8). Presumptive ZIKV infection was present in 0.8% of infants (IR = 1.6, 95% CI: 0.7–2.9). Five percent of infants with prenatal ZIKV exposure or infection presented with Zika-associated abnormalities; 4.7% were small for gestational age. Understanding the risk of ZIKV infection during pregnancy and associated adverse outcomes can help inform counseling efforts.
- Open Access
- 17 October 2022
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 75 (Supplement) , S339-S340
Responding to the Threat Posed by Anthrax: Updated Evidence to Improve Preparedness
For many Americans, awareness of the threat posed by anthrax is closely tied to the attacks of October 2001 and November 2001 when 22 persons were diagnosed with anthrax from exposure to intentionally contaminated mail [ 1]. That event highlighted the critical need to strengthen preparedness for this biothreat in the United States. Anthrax is a bacterial disease caused by Bacillus anthracis. The US Department of Health and Human Services designated B. anthracis as a tier 1 select agent, signifying that it presents the greatest risk of deliberate misuse with significant potential for mass causalities and poses a severe threat to public health and safety [ 2].
- 17 October 2022
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 75 (Supplement) , S339-S340
Open AccessResponding to the Threat Posed by Anthrax: Updated Evidence to Improve Preparedness
For many Americans, awareness of the threat posed by anthrax is closely tied to the attacks of October 2001 and November 2001 when 22 persons were diagnosed with anthrax from exposure to intentionally contaminated mail [ 1]. That event highlighted the critical need to strengthen preparedness for this biothreat in the United States. Anthrax is a bacterial disease caused by Bacillus anthracis. The US Department of Health and Human Services designated B. anthracis as a tier 1 select agent, signifying that it presents the greatest risk of deliberate misuse with significant potential for mass causalities and poses a severe threat to public health and safety [ 2].
- Open Access
- 12 October 2021
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 6 (4) , 183
Pregnancy, Birth, Infant, and Early Childhood Neurodevelopmental Outcomes among a Cohort of Women with Symptoms of Zika Virus Disease during Pregnancy in Three Surveillance Sites, Project Vigilancia de Embarazadas con Zika (VEZ), Colombia, 2016–2018
Project Vigilancia de Embarazadas con Zika (VEZ), an intensified surveillance of pregnant women with symptoms of the Zika virus disease (ZVD) in Colombia, aimed to evaluate the relationship between symptoms of ZVD during pregnancy and adverse pregnancy, birth, and infant outcomes and early childhood neurodevelopmental outcomes. During May–November 2016, pregnant women in three Colombian cities who were reported with symptoms of ZVD to the national surveillance system, or with symptoms of ZVD visiting participating clinics, were enrolled in Project VEZ. Data from maternal and pediatric (up to two years of age) medical records were abstracted. Available maternal specimens were tested for the presence of the Zika virus ribonucleic acid and/or anti-Zika virus immunoglobulin antibodies. Of 1213 enrolled pregnant women with symptoms of ZVD, 1180 had a known pregnancy outcome. Results of the Zika virus laboratory testing were available for 569 (48.2%) pregnancies with a known pregnancy outcome though testing timing varied and was often distal to the timing of symptoms; 254 (21.5% of the whole cohort; 44.6% of those with testing results) were confirmed or presumptive positive for the Zika virus infection. Of pregnancies with a known outcome, 50 (4.2%) fetuses/infants had Zika-associated brain or eye defects, which included microcephaly at birth. Early childhood adverse neurodevelopmental outcomes were more common among those with Zika-associated birth defects than among those without and more common among those with laboratory evidence of a Zika virus infection compared with the full cohort. The proportion of fetuses/infants with any Zika-associated brain or eye defect was consistent with the proportion seen in other studies. Enhancements to Colombia’s existing national surveillance enabled the assessment of adverse outcomes associated with ZVD in pregnancy.
- 12 October 2021
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 6 (4) , 183
Open AccessPregnancy, Birth, Infant, and Early Childhood Neurodevelopmental Outcomes among a Cohort of Women with Symptoms of Zika Virus Disease during Pregnancy in Three Surveillance Sites, Project Vigilancia de Embarazadas con Zika (VEZ), Colombia, 2016–2018
Project Vigilancia de Embarazadas con Zika (VEZ), an intensified surveillance of pregnant women with symptoms of the Zika virus disease (ZVD) in Colombia, aimed to evaluate the relationship between symptoms of ZVD during pregnancy and adverse pregnancy, birth, and infant outcomes and early childhood neurodevelopmental outcomes. During May–November 2016, pregnant women in three Colombian cities who were reported with symptoms of ZVD to the national surveillance system, or with symptoms of ZVD visiting participating clinics, were enrolled in Project VEZ. Data from maternal and pediatric (up to two years of age) medical records were abstracted. Available maternal specimens were tested for the presence of the Zika virus ribonucleic acid and/or anti-Zika virus immunoglobulin antibodies. Of 1213 enrolled pregnant women with symptoms of ZVD, 1180 had a known pregnancy outcome. Results of the Zika virus laboratory testing were available for 569 (48.2%) pregnancies with a known pregnancy outcome though testing timing varied and was often distal to the timing of symptoms; 254 (21.5% of the whole cohort; 44.6% of those with testing results) were confirmed or presumptive positive for the Zika virus infection. Of pregnancies with a known outcome, 50 (4.2%) fetuses/infants had Zika-associated brain or eye defects, which included microcephaly at birth. Early childhood adverse neurodevelopmental outcomes were more common among those with Zika-associated birth defects than among those without and more common among those with laboratory evidence of a Zika virus infection compared with the full cohort. The proportion of fetuses/infants with any Zika-associated brain or eye defect was consistent with the proportion seen in other studies. Enhancements to Colombia’s existing national surveillance enabled the assessment of adverse outcomes associated with ZVD in pregnancy.
- Open Access
- 2 March 2021
- Published by American Medical Association (AMA) in JAMA
- Vol. 325 (9) , 823-824
Data and Policy to Guide Opening Schools Safely to Limit the Spread of SARS-CoV-2 Infection
This Viewpoint from the CDC summarizes global data about SARS-CoV-2 outbreaks at K-12 schools and emphasizes implementation of community- and school-based polic
- 2 March 2021
- Published by American Medical Association (AMA) in JAMA
- Vol. 325 (9) , 823-824
Open AccessData and Policy to Guide Opening Schools Safely to Limit the Spread of SARS-CoV-2 Infection
This Viewpoint from the CDC summarizes global data about SARS-CoV-2 outbreaks at K-12 schools and emphasizes implementation of community- and school-based polic
- Top Cited Papers
- 11 December 2020
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 69 (49) , 1860-1867
Summary of Guidance for Public Health Strategies to Address High Levels of Community Transmission of SARS-CoV-2 and Related Deaths, December 2020
This report describes the need for implementation and adherence to mitigation strategies to reduce SARS-CoV-2 transmission and deaths.
- 11 December 2020
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 69 (49) , 1860-1867
Top Cited PapersSummary of Guidance for Public Health Strategies to Address High Levels of Community Transmission of SARS-CoV-2 and Related Deaths, December 2020
This report describes the need for implementation and adherence to mitigation strategies to reduce SARS-CoV-2 transmission and deaths.
- Top Cited PapersOpen Access
- 3 November 2020
- Published by American Medical Association (AMA) in JAMA
- Vol. 324 (17) , 1727-1728
Preventing and Responding to COVID-19 on College Campuses
This Viewpoint from CDC officials discusses late summer and early fall increases in COVID-19 cases among college-age students when they were returning to campus
- 3 November 2020
- Published by American Medical Association (AMA) in JAMA
- Vol. 324 (17) , 1727-1728
Top Cited PapersOpen AccessPreventing and Responding to COVID-19 on College Campuses
This Viewpoint from CDC officials discusses late summer and early fall increases in COVID-19 cases among college-age students when they were returning to campus
- 1 March 2020
- Published by American Medical Association (AMA) in JAMA Pediatrics
- Vol. 174 (3) , 237-238
Neurodevelopmental Abnormalities Associated With In Utero Zika Virus Infection in Infants and Children—The Unfolding Story
In the United States, more than 7400 pregnancies with laboratory evidence of confirmed or possible Zika virus infection were identified and included in the nati
- 1 March 2020
- Published by American Medical Association (AMA) in JAMA Pediatrics
- Vol. 174 (3) , 237-238
Neurodevelopmental Abnormalities Associated With In Utero Zika Virus Infection in Infants and Children—The Unfolding Story
In the United States, more than 7400 pregnancies with laboratory evidence of confirmed or possible Zika virus infection were identified and included in the nati
- Open Access
- 1 March 2019
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 143 (3) , e20183801
Public Health Surveillance of Prenatal Opioid Exposure in Mothers and Infants
* Abbreviation: NAS — : neonatal abstinence syndrome The US opioid crisis is the public health emergency of our time and requires urgent public health action to monitor and protect the most vulnerable Americans. We have witnessed a startling death toll in 2017 with 70 237 drug overdose deaths in the United States, of which two-thirds involved opioids.1 The devastating consequences of this epidemic for mothers and infants have received less attention. Increases in opioid use and misuse in pregnancy have paralleled the increases in the general population; at delivery hospitalization, there were 4 times as many women with an opioid use disorder in 2014 compared with 1999.2 One of the most immediate and visible impacts of the opioid crisis on infants is the drug withdrawal in the newborn period, termed neonatal abstinence syndrome (NAS). On the basis of 2014 data, 1 newborn was diagnosed with NAS every 15 minutes in the United States, totaling about 32 000 infants annually with associated hospital costs estimated at $563 million.3 Because prevention and treatment of opioid use disorder in pregnancy is important to both maternal and infant health, there is an urgent need to expand prevention efforts and reduce barriers for medication-assisted treatment before, during, and after pregnancy. The stigma of substance exposure during pregnancy and fears of punitive consequences can be obstacles to women receiving the treatment and care they need, and studies with inadequate control of cofactors can exaggerate the specific effects of an individual substance as occurred with … Address correspondence to Margaret A. Honein, PhD, MPH, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, 4770 Buford Hwy NE, Mailstop S106-3, Atlanta, GA 30341. E-mail: mrh7{at}cdc.gov
- 1 March 2019
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 143 (3) , e20183801
Open AccessPublic Health Surveillance of Prenatal Opioid Exposure in Mothers and Infants
* Abbreviation: NAS — : neonatal abstinence syndrome The US opioid crisis is the public health emergency of our time and requires urgent public health action to monitor and protect the most vulnerable Americans. We have witnessed a startling death toll in 2017 with 70 237 drug overdose deaths in the United States, of which two-thirds involved opioids.1 The devastating consequences of this epidemic for mothers and infants have received less attention. Increases in opioid use and misuse in pregnancy have paralleled the increases in the general population; at delivery hospitalization, there were 4 times as many women with an opioid use disorder in 2014 compared with 1999.2 One of the most immediate and visible impacts of the opioid crisis on infants is the drug withdrawal in the newborn period, termed neonatal abstinence syndrome (NAS). On the basis of 2014 data, 1 newborn was diagnosed with NAS every 15 minutes in the United States, totaling about 32 000 infants annually with associated hospital costs estimated at $563 million.3 Because prevention and treatment of opioid use disorder in pregnancy is important to both maternal and infant health, there is an urgent need to expand prevention efforts and reduce barriers for medication-assisted treatment before, during, and after pregnancy. The stigma of substance exposure during pregnancy and fears of punitive consequences can be obstacles to women receiving the treatment and care they need, and studies with inadequate control of cofactors can exaggerate the specific effects of an individual substance as occurred with … Address correspondence to Margaret A. Honein, PhD, MPH, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, 4770 Buford Hwy NE, Mailstop S106-3, Atlanta, GA 30341. E-mail: mrh7{at}cdc.gov
- 10 August 2018
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 67 (31) , 858-867
Vital Signs:Zika-Associated Birth Defects and Neurodevelopmental Abnormalities Possibly Associated with Congenital Zika Virus Infection — U.S. Territories and Freely Associated States, 2018
This report is the first analysis assessing neurodevelopmental abnormalities possibly associated with congenital Zika virus infection.
- 10 August 2018
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 67 (31) , 858-867
Vital Signs:Zika-Associated Birth Defects and Neurodevelopmental Abnormalities Possibly Associated with Congenital Zika Virus Infection — U.S. Territories and Freely Associated States, 2018
This report is the first analysis assessing neurodevelopmental abnormalities possibly associated with congenital Zika virus infection.
- 27 March 2018
- Published by American Medical Association (AMA) in JAMA
- Vol. 319 (12) , 1195-1196
Birth Defects Potentially Related to Zika Virus Infection During Pregnancy in the United States
This Viewpoint summarizes findings from a population-based birth defect surveillance report from the Centers for Disease Control and Prevention estimating the p
- 27 March 2018
- Published by American Medical Association (AMA) in JAMA
- Vol. 319 (12) , 1195-1196
Birth Defects Potentially Related to Zika Virus Infection During Pregnancy in the United States
This Viewpoint summarizes findings from a population-based birth defect surveillance report from the Centers for Disease Control and Prevention estimating the p